Genome-scale functional genomics identify genes preferentially essential for multiple myeloma cells compared to other neoplasias. Nat Cancer. 2023 05; 4(5):754-773.
View in:
PubMed
USP9X mediates an acute adaptive response to MAPK suppression in pancreatic cancer but creates multiple actionable therapeutic vulnerabilities. Cell Rep Med. 2023 04 18; 4(4):101007.
View in:
PubMed
Mapping the landscape of genetic dependencies in chordoma. Nat Commun. 2023 04 06; 14(1):1933.
View in:
PubMed
Aberrant cell state plasticity mediated by developmental reprogramming precedes colorectal cancer initiation. Sci Adv. 2023 03 29; 9(13):eadf0927.
View in:
PubMed
A Ubiquitination Cascade Regulating the Integrated Stress Response and Survival in Carcinomas. Cancer Discov. 2023 03 01; 13(3):766-795.
View in:
PubMed
Systematic Interrogation of Tumor Cell Resistance to Chimeric Antigen Receptor T-cell Therapy in Pancreatic Cancer. Cancer Res. 2023 02 15; 83(4):613-625.
View in:
PubMed
Spatially Resolved Single-Cell Assessment of Pancreatic Cancer Expression Subtypes Reveals Co-expressor Phenotypes and Extensive Intratumoral Heterogeneity. Cancer Res. 2023 02 03; 83(3):441-455.
View in:
PubMed
Discovery of antibodies and cognate surface targets for ovarian cancer by surface profiling. Proc Natl Acad Sci U S A. 2023 01 03; 120(1):e2206751120.
View in:
PubMed
Author Correction: Massively parallel phenotyping of coding variants in cancer with Perturb-seq. Nat Biotechnol. 2022 Nov; 40(11):1691.
View in:
PubMed
VRK1 as a synthetic lethal target in VRK2 promoter-methylated cancers of the nervous system. JCI Insight. 2022 10 10; 7(19).
View in:
PubMed
Structure-function analysis of the SHOC2-MRAS-PP1C holophosphatase complex. Nature. 2022 09; 609(7926):408-415.
View in:
PubMed
Phosphate dysregulation via the XPR1-KIDINS220 protein complex is a therapeutic vulnerability in ovarian cancer. Nat Cancer. 2022 06; 3(6):681-695.
View in:
PubMed
Serological testing for SARS-CoV-2 antibodies of employees shows low transmission working in a cancer center. PLoS One. 2022; 17(4):e0266791.
View in:
PubMed
Author Correction: Identification of ADAR1 adenosine deaminase dependency in a subset of cancer cells. Nat Commun. 2022 Apr 01; 13(1):1894.
View in:
PubMed
PI3K activation allows immune evasion by promoting an inhibitory myeloid tumor microenvironment. J Immunother Cancer. 2022 03; 10(3).
View in:
PubMed
A genome-scale CRISPR screen reveals PRMT1 as a critical regulator of androgen receptor signaling in prostate cancer. Cell Rep. 2022 02 22; 38(8):110417.
View in:
PubMed
Sparse dictionary learning recovers pleiotropy from human cell fitness screens. Cell Syst. 2022 04 20; 13(4):286-303.e10.
View in:
PubMed
Massively parallel phenotyping of coding variants in cancer with Perturb-seq. Nat Biotechnol. 2022 06; 40(6):896-905.
View in:
PubMed
YAP1 and PRDM14 converge to promote cell survival and tumorigenesis. Dev Cell. 2022 01 24; 57(2):212-227.e8.
View in:
PubMed
Chronos: a cell population dynamics model of CRISPR experiments that improves inference of gene fitness effects. Genome Biol. 2021 12 20; 22(1):343.
View in:
PubMed
Microenvironment drives cell state, plasticity, and drug response in pancreatic cancer. Cell. 2021 12 09; 184(25):6119-6137.e26.
View in:
PubMed
Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine. N Engl J Med. 2021 12 16; 385(25):2348-2360.
View in:
PubMed
Biologically informed deep neural network for prostate cancer discovery. Nature. 2021 10; 598(7880):348-352.
View in:
PubMed
SMAD4 represses FOSL1 expression and pancreatic cancer metastatic colonization. Cell Rep. 2021 07 27; 36(4):109443.
View in:
PubMed
Haplotype-resolved germline and somatic alterations in renal medullary carcinomas. Genome Med. 2021 07 14; 13(1):114.
View in:
PubMed
Synthetic Lethal Interaction between the ESCRT Paralog Enzymes VPS4A and VPS4B in Cancers Harboring Loss of Chromosome 18q or 16q. Cell Rep. 2021 Jul 13; 36(2):109367.
View in:
PubMed
FGFR2 Extracellular Domain In-Frame Deletions Are Therapeutically Targetable Genomic Alterations That Function as Oncogenic Drivers in Cholangiocarcinoma. Cancer Discov. 2021 10; 11(10):2488-2505.
View in:
PubMed
Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancer. Nat Commun. 2021 03 30; 12(1):1979.
View in:
PubMed
A Leucine-Rich Repeat Protein Provides a SHOC2 the RAS Circuit: a Structure-Function Perspective. Mol Cell Biol. 2021 03 24; 41(4).
View in:
PubMed
A first-generation pediatric cancer dependency map. Nat Genet. 2021 04; 53(4):529-538.
View in:
PubMed
An expanded universe of cancer targets. Cell. 2021 03 04; 184(5):1142-1155.
View in:
PubMed
Predicting cell health phenotypes using image-based morphology profiling. Mol Biol Cell. 2021 04 19; 32(9):995-1005.
View in:
PubMed
Functional Genomics Identify Distinct and Overlapping Genes Mediating Resistance to Different Classes of Heterobifunctional Degraders of Oncoproteins. Cell Rep. 2021 01 05; 34(1):108532.
View in:
PubMed
Global computational alignment of tumor and cell line transcriptional profiles. Nat Commun. 2021 01 04; 12(1):22.
View in:
PubMed
Cancer research needs a better map. Nature. 2021 01; 589(7843):514-516.
View in:
PubMed
Synthetic Lethal Interaction between the ESCRT Paralog Enzymes VPS4A and VPS4B in Cancers Harboring Loss of Chromosome 18q or 16q. Cell Rep. 2020 12 15; 33(11):108493.
View in:
PubMed
Rhabdoid Tumors Are Sensitive to the Protein-Translation Inhibitor Homoharringtonine. Clin Cancer Res. 2020 09 15; 26(18):4995-5006.
View in:
PubMed
Discovery of a selective inhibitor of doublecortin like kinase 1. Nat Chem Biol. 2020 06; 16(6):635-643.
View in:
PubMed
Selective USP7 inhibition elicits cancer cell killing through a p53-dependent mechanism. Sci Rep. 2020 03 24; 10(1):5324.
View in:
PubMed
ATM Loss Confers Greater Sensitivity to ATR Inhibition Than PARP Inhibition in Prostate Cancer. Cancer Res. 2020 06 01; 80(11):2094-2100.
View in:
PubMed
STRIPAK directs PP2A activity toward MAP4K4 to promote oncogenic transformation of human cells. Elife. 2020 Jan 08; 9.
View in:
PubMed
Agreement between two large pan-cancer CRISPR-Cas9 gene dependency data sets. Nat Commun. 2019 12 20; 10(1):5817.
View in:
PubMed
CREB5 Promotes Resistance to Androgen-Receptor Antagonists and Androgen Deprivation in Prostate Cancer. Cell Rep. 2019 11 19; 29(8):2355-2370.e6.
View in:
PubMed
Synthetic Lethal Interaction of SHOC2 Depletion with MEK Inhibition in RAS-Driven Cancers. Cell Rep. 2019 10 01; 29(1):118-134.e8.
View in:
PubMed
Small-Molecule and CRISPR Screening Converge to Reveal Receptor Tyrosine Kinase Dependencies in Pediatric Rhabdoid Tumors. Cell Rep. 2019 08 27; 28(9):2331-2344.e8.
View in:
PubMed
A dominant-negative effect drives selection of TP53 missense mutations in myeloid malignancies. Science. 2019 08 09; 365(6453):599-604.
View in:
PubMed
A CRISPR Way to Identify Cancer Targets. N Engl J Med. 2019 Jun 20; 380(25):2475-2477.
View in:
PubMed
Neuronal differentiation and cell-cycle programs mediate response to BET-bromodomain inhibition in MYC-driven medulloblastoma. Nat Commun. 2019 06 03; 10(1):2400.
View in:
PubMed
TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion-Positive Intrahepatic Cholangiocarcinoma. Cancer Discov. 2019 08; 9(8):1064-1079.
View in:
PubMed
Next-generation characterization of the Cancer Cell Line Encyclopedia. Nature. 2019 05; 569(7757):503-508.
View in:
PubMed
The landscape of cancer cell line metabolism. Nat Med. 2019 05; 25(5):850-860.
View in:
PubMed
Genome-Wide Interrogation of Human Cancers Identifies EGLN1 Dependency in Clear Cell Ovarian Cancers. Cancer Res. 2019 05 15; 79(10):2564-2579.
View in:
PubMed
Renal medullary carcinomas depend upon SMARCB1 loss and are sensitive to proteasome inhibition. Elife. 2019 03 12; 8.
View in:
PubMed
Deubiquitinases Maintain Protein Homeostasis and Survival of Cancer Cells upon Glutathione Depletion. Cell Metab. 2019 05 07; 29(5):1166-1181.e6.
View in:
PubMed
MCL1 and DEDD Promote Urothelial Carcinoma Progression. Mol Cancer Res. 2019 06; 17(6):1294-1304.
View in:
PubMed
MDM2 and MDM4 Are Therapeutic Vulnerabilities in Malignant Rhabdoid Tumors. Cancer Res. 2019 05 01; 79(9):2404-2414.
View in:
PubMed
Small-molecule targeting of brachyury transcription factor addiction in chordoma. Nat Med. 2019 02; 25(2):292-300.
View in:
PubMed
Identification of ADAR1 adenosine deaminase dependency in a subset of cancer cells. Nat Commun. 2018 12 21; 9(1):5450.
View in:
PubMed
Organoid Modeling of the Tumor Immune Microenvironment. Cell. 2018 12 13; 175(7):1972-1988.e16.
View in:
PubMed
Tumor fraction in cell-free DNA as a biomarker in prostate cancer. JCI Insight. 2018 11 02; 3(21).
View in:
PubMed
Improved estimation of cancer dependencies from large-scale RNAi screens using model-based normalization and data integration. Nat Commun. 2018 11 02; 9(1):4610.
View in:
PubMed
Mutational processes shape the landscape of TP53 mutations in human cancer. Nat Genet. 2018 10; 50(10):1381-1387.
View in:
PubMed
Selective gene dependencies in MYCN-amplified neuroblastoma include the core transcriptional regulatory circuitry. Nat Genet. 2018 09; 50(9):1240-1246.
View in:
PubMed
iRGD-guided Tumor-penetrating Nanocomplexes for Therapeutic siRNA Delivery to Pancreatic Cancer. Mol Cancer Ther. 2018 11; 17(11):2377-2388.
View in:
PubMed
Binding of TMPRSS2-ERG to BAF Chromatin Remodeling Complexes Mediates Prostate Oncogenesis. Mol Cell. 2018 08 16; 71(4):554-566.e7.
View in:
PubMed
Synthetic Lethal Vulnerabilities in KRAS-Mutant Cancers. Cold Spring Harb Perspect Med. 2018 08 01; 8(8).
View in:
PubMed
Phase 1 dose-escalation study of momelotinib, a Janus kinase 1/2 inhibitor, combined with gemcitabine and nab-paclitaxel in patients with previously untreated metastatic pancreatic ductal adenocarcinoma. Invest New Drugs. 2019 02; 37(1):159-165.
View in:
PubMed
An alternative splicing switch in FLNB promotes the mesenchymal cell state in human breast cancer. Elife. 2018 07 30; 7.
View in:
PubMed
Germline cancer susceptibility gene variants, somatic second hits, and survival outcomes in patients with resected pancreatic cancer. Genet Med. 2019 01; 21(1):213-223.
View in:
PubMed
Genome-scale analysis identifies paralog lethality as a vulnerability of chromosome 1p loss in cancer. Nat Genet. 2018 07; 50(7):937-943.
View in:
PubMed
Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine. Cancer Discov. 2018 09; 8(9):1096-1111.
View in:
PubMed
A Somatically Acquired Enhancer of the Androgen Receptor Is a Noncoding Driver in Advanced Prostate Cancer. Cell. 2018 07 12; 174(2):422-432.e13.
View in:
PubMed
Targetable vulnerabilities in T- and NK-cell lymphomas identified through preclinical models. Nat Commun. 2018 05 22; 9(1):2024.
View in:
PubMed
Interrogation of Mammalian Protein Complex Structure, Function, and Membership Using Genome-Scale Fitness Screens. Cell Syst. 2018 05 23; 6(5):555-568.e7.
View in:
PubMed
Association of Alterations in Main Driver Genes With Outcomes of Patients With Resected Pancreatic Ductal Adenocarcinoma. JAMA Oncol. 2018 Mar 08; 4(3):e173420.
View in:
PubMed
Genomic Resistance Patterns to Second-Generation Androgen Blockade in Paired Tumor Biopsies of Metastatic Castration-Resistant Prostate Cancer. JCO Precis Oncol. 2017; 1.
View in:
PubMed
NetSig: network-based discovery from cancer genomes. Nat Methods. 2018 01; 15(1):61-66.
View in:
PubMed
CRISPR-Cas9 screen reveals a MYCN-amplified neuroblastoma dependency on EZH2. J Clin Invest. 2018 01 02; 128(1):446-462.
View in:
PubMed
Analysis of Fusobacterium persistence and antibiotic response in colorectal cancer. Science. 2017 12 15; 358(6369):1443-1448.
View in:
PubMed
Correction: KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer. Elife. 2017 10 31; 6.
View in:
PubMed
Computational correction of copy number effect improves specificity of CRISPR-Cas9 essentiality screens in cancer cells. Nat Genet. 2017 Dec; 49(12):1779-1784.
View in:
PubMed
A Community Challenge for Inferring Genetic Predictors of Gene Essentialities through Analysis of a Functional Screen of Cancer Cell Lines. Cell Syst. 2017 11 22; 5(5):485-497.e3.
View in:
PubMed
Somatic Superenhancer Duplications and Hotspot Mutations Lead to Oncogenic Activation of the KLF5 Transcription Factor. Cancer Discov. 2018 01; 8(1):108-125.
View in:
PubMed
Decomposing Oncogenic Transcriptional Signatures to Generate Maps of Divergent Cellular States. Cell Syst. 2017 08 23; 5(2):105-118.e9.
View in:
PubMed
Defining a Cancer Dependency Map. Cell. 2017 Jul 27; 170(3):564-576.e16.
View in:
PubMed
Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway. Nature. 2017 07 27; 547(7664):453-457.
View in:
PubMed
PRMT1-Mediated Translation Regulation Is a Crucial Vulnerability of Cancer. Cancer Res. 2017 09 01; 77(17):4613-4625.
View in:
PubMed
Corrigendum: PARP3 is a promoter of chromosomal rearrangements and limits G4 DNA. Nat Commun. 2017 06 13; 8:15918.
View in:
PubMed
A brain-penetrant RAF dimer antagonist for the noncanonical BRAF oncoprotein of pediatric low-grade astrocytomas. Neuro Oncol. 2017 06 01; 19(6):774-785.
View in:
PubMed
Synergistic interactions with PI3K inhibition that induce apoptosis. Elife. 2017 05 31; 6.
View in:
PubMed
Complementary information derived from CRISPR Cas9 mediated gene deletion and suppression. Nat Commun. 2017 05 23; 8:15403.
View in:
PubMed
Going beyond genetics to discover cancer targets. Genome Biol. 2017 05 22; 18(1):95.
View in:
PubMed
PARP3 is a promoter of chromosomal rearrangements and limits G4 DNA. Nat Commun. 2017 04 27; 8:15110.
View in:
PubMed
PIK3CA mutant tumors depend on oxoglutarate dehydrogenase. Proc Natl Acad Sci U S A. 2017 04 25; 114(17):E3434-E3443.
View in:
PubMed
Copy-number and gene dependency analysis reveals partial copy loss of wild-type SF3B1 as a novel cancer vulnerability. Elife. 2017 02 08; 6.
View in:
PubMed
ATXN1L, CIC, and ETS Transcription Factors Modulate Sensitivity to MAPK Pathway Inhibition. Cell Rep. 2017 02 07; 18(6):1543-1557.
View in:
PubMed
KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer. Elife. 2017 02 01; 6.
View in:
PubMed
Castration Resistance in Prostate Cancer Is Mediated by the Kinase NEK6. Cancer Res. 2017 02 01; 77(3):753-765.
View in:
PubMed
Institutional implementation of clinical tumor profiling on an unselected cancer population. JCI Insight. 2016 11 17; 1(19):e87062.
View in:
PubMed
Functional Genomic Characterization of Cancer Genomes. Cold Spring Harb Symp Quant Biol. 2016; 81:237-246.
View in:
PubMed
The EMT regulator ZEB2 is a novel dependency of human and murine acute myeloid leukemia. Blood. 2017 01 26; 129(4):497-508.
View in:
PubMed
Genetic and Proteomic Interrogation of Lower Confidence Candidate Genes Reveals Signaling Networks in ß-Catenin-Active Cancers. Cell Syst. 2016 09 28; 3(3):302-316.e4.
View in:
PubMed
Tyrosine receptor kinase B is a drug target in astrocytomas. Neuro Oncol. 2017 01; 19(1):22-30.
View in:
PubMed
Association of tumour microRNA profiling with outcomes in patients with advanced urothelial carcinoma receiving first-line platinum-based chemotherapy. Br J Cancer. 2016 06 28; 115(1):12-9.
View in:
PubMed
Integrated genetic and pharmacologic interrogation of rare cancers. Nat Commun. 2016 06 22; 7:11987.
View in:
PubMed
Genomic Copy Number Dictates a Gene-Independent Cell Response to CRISPR/Cas9 Targeting. Cancer Discov. 2016 08; 6(8):914-29.
View in:
PubMed
Systematic Functional Interrogation of Rare Cancer Variants Identifies Oncogenic Alleles. Cancer Discov. 2016 07; 6(7):714-26.
View in:
PubMed
Characterizing genomic alterations in cancer by complementary functional associations. Nat Biotechnol. 2016 05; 34(5):539-46.
View in:
PubMed
MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells. Science. 2016 Mar 11; 351(6278):1214-8.
View in:
PubMed
TERT promoter mutations and monoallelic activation of TERT in cancer. Oncogenesis. 2015 Dec 14; 4:e176.
View in:
PubMed
Identification of an "Exceptional Responder" Cell Line to MEK1 Inhibition: Clinical Implications for MEK-Targeted Therapy. Mol Cancer Res. 2016 Feb; 14(2):207-15.
View in:
PubMed
SWI/SNF-mutant cancers depend on catalytic and non-catalytic activity of EZH2. Nat Med. 2015 Dec; 21(12):1491-6.
View in:
PubMed
Functional genomic screening reveals asparagine dependence as a metabolic vulnerability in sarcoma. Elife. 2015 Oct 24; 4.
View in:
PubMed
The androgen receptor cistrome is extensively reprogrammed in human prostate tumorigenesis. Nat Genet. 2015 Nov; 47(11):1346-51.
View in:
PubMed
AACR Cancer Progress Report 2015. Clin Cancer Res. 2015 Oct 01; 21(19 Suppl):S1-128.
View in:
PubMed
Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. Cancer Discov. 2015 Nov; 5(11):1164-1177.
View in:
PubMed
Oncogenic Signaling Adaptor Proteins. J Genet Genomics. 2015 Oct 20; 42(10):521-529.
View in:
PubMed
Rapid Intraoperative Molecular Characterization of Glioma. JAMA Oncol. 2015 Aug; 1(5):662-7.
View in:
PubMed
Correction for Hwang et al., Polyomavirus small T antigen interacts with yes-associated protein to regulate cell survival and differentiation. J Virol. 2015 Jul; 89(13):6971.
View in:
PubMed
DOT1L inhibits SIRT1-mediated epigenetic silencing to maintain leukemic gene expression in MLL-rearranged leukemia. Nat Med. 2015 Apr; 21(4):335-43.
View in:
PubMed
A functional landscape of resistance to ALK inhibition in lung cancer. Cancer Cell. 2015 Mar 09; 27(3):397-408.
View in:
PubMed
Papillomavirus E7 oncoproteins share functions with polyomavirus small T antigens. J Virol. 2015 Mar; 89(5):2857-65.
View in:
PubMed
An in-tumor genetic screen reveals that the BET bromodomain protein, BRD4, is a potential therapeutic target in ovarian carcinoma. Proc Natl Acad Sci U S A. 2015 Jan 06; 112(1):232-7.
View in:
PubMed
BreaKmer: detection of structural variation in targeted massively parallel sequencing data using kmers. Nucleic Acids Res. 2015 Feb 18; 43(3):e19.
View in:
PubMed
Erratum: Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies. Sci Data. 2014; 1:140044.
View in:
PubMed
The Tyrosine Kinase Adaptor Protein FRS2 Is Oncogenic and Amplified in High-Grade Serous Ovarian Cancer. Mol Cancer Res. 2015 Mar; 13(3):502-9.
View in:
PubMed
Targeting an IKBKE cytokine network impairs triple-negative breast cancer growth. J Clin Invest. 2014 Dec; 124(12):5411-23.
View in:
PubMed
RNF43 is frequently mutated in colorectal and endometrial cancers. Nat Genet. 2014 Dec; 46(12):1264-6.
View in:
PubMed
Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies. Sci Data. 2014; 1:140035.
View in:
PubMed
The role of specific PP2A complexes in the dephosphorylation of ?H2AX. J Cell Sci. 2015 Jan 15; 128(2):421.
View in:
PubMed
Prospective enterprise-level molecular genotyping of a cohort of cancer patients. J Mol Diagn. 2014 Nov; 16(6):660-72.
View in:
PubMed
Polyomavirus small T antigen interacts with yes-associated protein to regulate cell survival and differentiation. J Virol. 2014 Oct; 88(20):12055-64.
View in:
PubMed
Analysis of tumour- and stroma-supplied proteolytic networks reveals a brain-metastasis-promoting role for cathepsin S. Nat Cell Biol. 2014 Sep; 16(9):876-88.
View in:
PubMed
KRAS and YAP1 converge to regulate EMT and tumor survival. Cell. 2014 Jul 03; 158(1):171-84.
View in:
PubMed
Analysis and comparison of somatic mutations in paired primary and recurrent epithelial ovarian cancer samples. PLoS One. 2014; 9(6):e99451.
View in:
PubMed
PRKACA mediates resistance to HER2-targeted therapy in breast cancer cells and restores anti-apoptotic signaling. Oncogene. 2015 Apr 16; 34(16):2061-71.
View in:
PubMed
PP2A-mediated regulation of Ras signaling in G2 is essential for stable quiescence and normal G1 length. Mol Cell. 2014 Jun 19; 54(6):932-945.
View in:
PubMed
A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors. Cancer Discov. 2014 Jul; 4(7):816-27.
View in:
PubMed
Requirement for CDK6 in MLL-rearranged acute myeloid leukemia. Blood. 2014 Jul 03; 124(1):13-23.
View in:
PubMed
Triplication of a 21q22 region contributes to B cell transformation through HMGN1 overexpression and loss of histone H3 Lys27 trimethylation. Nat Genet. 2014 Jun; 46(6):618-23.
View in:
PubMed
Whole-exome sequencing of circulating tumor cells provides a window into metastatic prostate cancer. Nat Biotechnol. 2014 May; 32(5):479-84.
View in:
PubMed
ARID1B is a specific vulnerability in ARID1A-mutant cancers. Nat Med. 2014 Mar; 20(3):251-4.
View in:
PubMed
Functional analysis of single cells identifies a rare subset of circulating tumor cells with malignant traits. Integr Biol (Camb). 2014 Apr; 6(4):388-98.
View in:
PubMed
Integrative analysis of 1q23.3 copy-number gain in metastatic urothelial carcinoma. Clin Cancer Res. 2014 Apr 01; 20(7):1873-83.
View in:
PubMed
Inhibition of KRAS-driven tumorigenicity by interruption of an autocrine cytokine circuit. Cancer Discov. 2014 Apr; 4(4):452-65.
View in:
PubMed
ZFHX4 interacts with the NuRD core member CHD4 and regulates the glioblastoma tumor-initiating cell state. Cell Rep. 2014 Jan 30; 6(2):313-24.
View in:
PubMed
Residual complexes containing SMARCA2 (BRM) underlie the oncogenic drive of SMARCA4 (BRG1) mutation. Mol Cell Biol. 2014 Mar; 34(6):1136-44.
View in:
PubMed
Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas. Nat Genet. 2014 Feb; 46(2):161-5.
View in:
PubMed
In vivo multiplexed interrogation of amplified genes identifies GAB2 as an ovarian cancer oncogene. Proc Natl Acad Sci U S A. 2014 Jan 21; 111(3):1102-7.
View in:
PubMed
TRAF2 is an NF-?B-activating oncogene in epithelial cancers. Oncogene. 2015 Jan 08; 34(2):209-16.
View in:
PubMed
Genomic insights into WNT/ß-catenin signaling. Trends Pharmacol Sci. 2014 Feb; 35(2):103-9.
View in:
PubMed
An integrative analysis reveals functional targets of GATA6 transcriptional regulation in gastric cancer. Oncogene. 2014 Dec 04; 33(49):5637-48.
View in:
PubMed
Synthetic lethality between CCNE1 amplification and loss of BRCA1. Proc Natl Acad Sci U S A. 2013 Nov 26; 110(48):19489-94.
View in:
PubMed
The perfect storm: challenges and opportunities for translational medicine. J Clin Invest. 2013 Nov; 123(11):4963-6.
View in:
PubMed
A Case of Persistent Helicobacter pylori Infection Occurring with Anti-IgE Immunosuppression. ACG Case Rep J. 2013 Oct; 1(1):16-8.
View in:
PubMed
Colorectal cancers from distinct ancestral populations show variations in BRAF mutation frequency. PLoS One. 2013; 8(9):e74950.
View in:
PubMed
Resistance to CDK2 inhibitors is associated with selection of polyploid cells in CCNE1-amplified ovarian cancer. Clin Cancer Res. 2013 Nov 01; 19(21):5960-71.
View in:
PubMed
Oncogenic mutations in cervical cancer: genomic differences between adenocarcinomas and squamous cell carcinomas of the cervix. Cancer. 2013 Nov 01; 119(21):3776-83.
View in:
PubMed
Systematic interrogation of 3q26 identifies TLOC1 and SKIL as cancer drivers. Cancer Discov. 2013 Sep; 3(9):1044-57.
View in:
PubMed
HIF1A employs CDK8-mediator to stimulate RNAPII elongation in response to hypoxia. Cell. 2013 Jun 06; 153(6):1327-39.
View in:
PubMed
The bromodomain protein Brd4 insulates chromatin from DNA damage signalling. Nature. 2013 Jun 13; 498(7453):246-50.
View in:
PubMed
RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer. J Clin Invest. 2013 Jun; 123(6):2551-63.
View in:
PubMed
Genomic analysis of diffuse pediatric low-grade gliomas identifies recurrent oncogenic truncating rearrangements in the transcription factor MYBL1. Proc Natl Acad Sci U S A. 2013 May 14; 110(20):8188-93.
View in:
PubMed
Structure and ubiquitination-dependent activation of TANK-binding kinase 1. Cell Rep. 2013 Mar 28; 3(3):747-58.
View in:
PubMed
IKKe-mediated tumorigenesis requires K63-linked polyubiquitination by a cIAP1/cIAP2/TRAF2 E3 ubiquitin ligase complex. Cell Rep. 2013 Mar 28; 3(3):724-33.
View in:
PubMed
Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations. Nat Genet. 2013 Mar; 45(3):285-9.
View in:
PubMed
Integrated cistromic and expression analysis of amplified NKX2-1 in lung adenocarcinoma identifies LMO3 as a functional transcriptional target. Genes Dev. 2013 Jan 15; 27(2):197-210.
View in:
PubMed
ATARiS: computational quantification of gene suppression phenotypes from multisample RNAi screens. Genome Res. 2013 Apr; 23(4):665-78.
View in:
PubMed
ß-Catenin-driven cancers require a YAP1 transcriptional complex for survival and tumorigenesis. Cell. 2012 Dec 21; 151(7):1457-73.
View in:
PubMed
Integrative functional genomics identifies RINT1 as a novel GBM oncogene. Neuro Oncol. 2012 Nov; 14(11):1325-31.
View in:
PubMed
High throughput mass spectrometry-based mutation profiling of primary uveal melanoma. Invest Ophthalmol Vis Sci. 2012 Oct 09; 53(11):6991-6.
View in:
PubMed
I?B kinase e phosphorylates TRAF2 to promote mammary epithelial cell transformation. Mol Cell Biol. 2012 Dec; 32(23):4756-68.
View in:
PubMed
Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2. Proc Natl Acad Sci U S A. 2012 Sep 04; 109(36):14476-81.
View in:
PubMed
Cancer vulnerabilities unveiled by genomic loss. Cell. 2012 Aug 17; 150(4):842-54.
View in:
PubMed
Targeted tumor-penetrating siRNA nanocomplexes for credentialing the ovarian cancer oncogene ID4. Sci Transl Med. 2012 Aug 15; 4(147):147ra112.
View in:
PubMed
Nek4 regulates entry into replicative senescence and the response to DNA damage in human fibroblasts. Mol Cell Biol. 2012 Oct; 32(19):3963-77.
View in:
PubMed
Loss of ATRX, genome instability, and an altered DNA damage response are hallmarks of the alternative lengthening of telomeres pathway. PLoS Genet. 2012; 8(7):e1002772.
View in:
PubMed
Genetic and functional analyses implicate the NUDT11, HNF1B, and SLC22A3 genes in prostate cancer pathogenesis. Proc Natl Acad Sci U S A. 2012 Jul 10; 109(28):11252-7.
View in:
PubMed
Prolonged early G(1) arrest by selective CDK4/CDK6 inhibition sensitizes myeloma cells to cytotoxic killing through cell cycle-coupled loss of IRF4. Blood. 2012 Aug 02; 120(5):1095-106.
View in:
PubMed
Tyrosine kinase pathways modulate tumor susceptibility to natural killer cells. J Clin Invest. 2012 Jul; 122(7):2369-83.
View in:
PubMed
MicroSCALE screening reveals genetic modifiers of therapeutic response in melanoma. Sci Signal. 2012 May 15; 5(224):rs4.
View in:
PubMed
EGFR in limbo. Cell. 2012 May 11; 149(4):735-7.
View in:
PubMed
Emerging insights into the molecular and cellular basis of glioblastoma. Genes Dev. 2012 Apr 15; 26(8):756-84.
View in:
PubMed
The intersection of genetic and chemical genomic screens identifies GSK-3a as a target in human acute myeloid leukemia. J Clin Invest. 2012 Mar; 122(3):935-47.
View in:
PubMed
PAK1 is a breast cancer oncogene that coordinately activates MAPK and MET signaling. Oncogene. 2012 Jul 19; 31(29):3397-408.
View in:
PubMed
High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing. Cancer Discov. 2012 Jan; 2(1):82-93.
View in:
PubMed
RMRP is a non-coding RNA essential for early murine development. PLoS One. 2011; 6(10):e26270.
View in:
PubMed
Amplification of CRKL induces transformation and epidermal growth factor receptor inhibitor resistance in human non-small cell lung cancers. Cancer Discov. 2011 Dec; 1(7):608-25.
View in:
PubMed
High throughput interrogation of somatic mutations in high grade serous cancer of the ovary. PLoS One. 2011; 6(9):e24433.
View in:
PubMed
Genomic sequencing of colorectal adenocarcinomas identifies a recurrent VTI1A-TCF7L2 fusion. Nat Genet. 2011 Sep 04; 43(10):964-968.
View in:
PubMed
BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell. 2011 Sep 16; 146(6):904-17.
View in:
PubMed
Clinical implementation of comprehensive strategies to characterize cancer genomes: opportunities and challenges. Cancer Discov. 2011 Sep; 1(4):297-311.
View in:
PubMed
Systematic investigation of genetic vulnerabilities across cancer cell lines reveals lineage-specific dependencies in ovarian cancer. Proc Natl Acad Sci U S A. 2011 Jul 26; 108(30):12372-7.
View in:
PubMed
Maintenance of tumor initiating cells of defined genetic composition by nucleostemin. Proc Natl Acad Sci U S A. 2011 Dec 20; 108(51):20388-93.
View in:
PubMed
The JAK2/STAT3 signaling pathway is required for growth of CD44?CD24? stem cell-like breast cancer cells in human tumors. J Clin Invest. 2011 Jul; 121(7):2723-35.
View in:
PubMed
A public genome-scale lentiviral expression library of human ORFs. Nat Methods. 2011 Jun 26; 8(8):659-61.
View in:
PubMed
Transformation-dependent silencing of tumor-selective apoptosis-inducing TRAIL by DNA hypermethylation is antagonized by decitabine. Mol Cancer Ther. 2011 Sep; 10(9):1611-23.
View in:
PubMed
Towards systematic functional characterization of cancer genomes. Nat Rev Genet. 2011 Jun 17; 12(7):487-98.
View in:
PubMed
Identification of a novel urothelial carcinoma (UC) biomarker of lethality. J Clin Oncol. 2011 May 20; 29(15_suppl):4569.
View in:
PubMed
Tumor genomic profiling of FFPE samples by massively parallel sequencing. J Clin Oncol. 2011 May 20; 29(15_suppl):10502.
View in:
PubMed
Initial genome sequencing and analysis of multiple myeloma. Nature. 2011 Mar 24; 471(7339):467-72.
View in:
PubMed
Making sense of cancer genomic data. Genes Dev. 2011 Mar 15; 25(6):534-55.
View in:
PubMed
Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol. 2011 Aug 01; 29(22):3085-96.
View in:
PubMed
Interplay between oncogene-induced DNA damage response and heterochromatin in senescence and cancer. Nat Cell Biol. 2011 Mar; 13(3):292-302.
View in:
PubMed
Therapeutic implications of GIPC1 silencing in cancer. PLoS One. 2010 Dec 30; 5(12):e15581.
View in:
PubMed
Identification of PP2A complexes and pathways involved in cell transformation. Cancer Res. 2010 Dec 15; 70(24):10474-84.
View in:
PubMed
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature. 2010 Dec 16; 468(7326):968-72.
View in:
PubMed
Developing a library of authenticated Traditional Chinese Medicinal (TCM) plants for systematic biological evaluation--rationale, methods and preliminary results from a Sino-American collaboration. Fitoterapia. 2011 Jan; 82(1):17-33.
View in:
PubMed
Analysis of the 10q11 cancer risk locus implicates MSMB and NCOA4 in human prostate tumorigenesis. PLoS Genet. 2010 Nov 11; 6(11):e1001204.
View in:
PubMed
Emerging roles for the non-canonical IKKs in cancer. Oncogene. 2011 Feb 10; 30(6):631-41.
View in:
PubMed
CDK9 regulates AR promoter selectivity and cell growth through serine 81 phosphorylation. Mol Endocrinol. 2010 Dec; 24(12):2267-80.
View in:
PubMed
Wilms tumor 1 (WT1) regulates KRAS-driven oncogenesis and senescence in mouse and human models. J Clin Invest. 2010 Nov; 120(11):3940-52.
View in:
PubMed
Towards patient-based cancer therapeutics. Nat Biotechnol. 2010 Sep; 28(9):904-6.
View in:
PubMed
Naked DNA expressing two isoforms of hepatocyte growth factor induces collateral artery augmentation in a rabbit model of limb ischemia. Gene Ther. 2010 Dec; 17(12):1442-52.
View in:
PubMed
PTK6 regulates IGF-1-induced anchorage-independent survival. PLoS One. 2010 Jul 23; 5(7):e11729.
View in:
PubMed
CDK8 expression in 470 colorectal cancers in relation to beta-catenin activation, other molecular alterations and patient survival. Int J Cancer. 2010 Jun 15; 126(12):2863-73.
View in:
PubMed
On or off target: mutations, models, and predictions. Sci Transl Med. 2010 Jun 09; 2(35):35ps28.
View in:
PubMed
Pattern of retinoblastoma pathway inactivation dictates response to CDK4/6 inhibition in GBM. Proc Natl Acad Sci U S A. 2010 Jun 22; 107(25):11501-6.
View in:
PubMed
Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood. 2010 Sep 16; 116(11):1919-23.
View in:
PubMed
Functional genomics and cancer drug target discovery. Curr Opin Mol Ther. 2010 Jun; 12(3):284-93.
View in:
PubMed
PLAGL2 regulates Wnt signaling to impede differentiation in neural stem cells and gliomas. Cancer Cell. 2010 May 18; 17(5):497-509.
View in:
PubMed
An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cells. Cancer Cell. 2010 Mar 16; 17(3):298-310.
View in:
PubMed
An oncogenic role for ETV1 in melanoma. Cancer Res. 2010 Mar 01; 70(5):2075-84.
View in:
PubMed
An oncogene-tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-kappaB. Nat Med. 2010 Mar; 16(3):286-94.
View in:
PubMed
CK1epsilon is required for breast cancers dependent on beta-catenin activity. PLoS One. 2010 Feb 01; 5(2):e8979.
View in:
PubMed
Protein phosphatase 2A reactivates FOXO3a through a dynamic interplay with 14-3-3 and AKT. Mol Biol Cell. 2010 Mar 15; 21(6):1140-52.
View in:
PubMed
Profiling critical cancer gene mutations in clinical tumor samples. PLoS One. 2009 Nov 18; 4(11):e7887.
View in:
PubMed
Control of cyclin D1 and breast tumorigenesis by the EglN2 prolyl hydroxylase. Cancer Cell. 2009 Nov 06; 16(5):413-24.
View in:
PubMed
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature. 2009 Nov 05; 462(7269):108-12.
View in:
PubMed
Regulating TERT: location, location, location. Cell Cycle. 2009 Oct 15; 8(20):3257.
View in:
PubMed
Revving the Throttle on an oncogene: CDK8 takes the driver seat. Cancer Res. 2009 Oct 15; 69(20):7899-901.
View in:
PubMed
Proteomic and genetic approaches identify Syk as an AML target. Cancer Cell. 2009 Oct 06; 16(4):281-94.
View in:
PubMed
SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet. 2009 Nov; 41(11):1238-42.
View in:
PubMed
MYC activity mitigates response to rapamycin in prostate cancer through eukaryotic initiation factor 4E-binding protein 1-mediated inhibition of autophagy. Cancer Res. 2009 Oct 01; 69(19):7803-10.
View in:
PubMed
An RNA-dependent RNA polymerase formed by TERT and the RMRP RNA. Nature. 2009 Sep 10; 461(7261):230-5.
View in:
PubMed
SIK1 couples LKB1 to p53-dependent anoikis and suppresses metastasis. Sci Signal. 2009 Jul 21; 2(80):ra35.
View in:
PubMed
AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. Cancer Cell. 2009 Jul 07; 16(1):21-32.
View in:
PubMed
Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell. 2009 May 29; 137(5):821-34.
View in:
PubMed
Phosphorylation of the tumor suppressor CYLD by the breast cancer oncogene IKKepsilon promotes cell transformation. Mol Cell. 2009 May 14; 34(4):461-72.
View in:
PubMed
Fatty acid synthase: a metabolic enzyme and candidate oncogene in prostate cancer. J Natl Cancer Inst. 2009 Apr 01; 101(7):519-32.
View in:
PubMed
PME-1 protects extracellular signal-regulated kinase pathway activity from protein phosphatase 2A-mediated inactivation in human malignant glioma. Cancer Res. 2009 Apr 01; 69(7):2870-7.
View in:
PubMed
Bladder cancer: modeling and translation. Genes Dev. 2009 Mar 15; 23(6):655-9.
View in:
PubMed
Integrative genomic approaches to understanding cancer. Biochim Biophys Acta. 2009 Jun; 1790(6):478-84.
View in:
PubMed
Genetic and cellular mechanisms of oncogenesis. Curr Opin Genet Dev. 2009 Feb; 19(1):1-3.
View in:
PubMed
Highly parallel identification of essential genes in cancer cells. Proc Natl Acad Sci U S A. 2008 Dec 23; 105(51):20380-5.
View in:
PubMed
BRAF activation initiates but does not maintain invasive prostate adenocarcinoma. PLoS One. 2008; 3(12):e3949.
View in:
PubMed
Genomic alterations link Rho family of GTPases to the highly invasive phenotype of pancreas cancer. Proc Natl Acad Sci U S A. 2008 Dec 09; 105(49):19372-7.
View in:
PubMed
Suppression of hPOT1 in diploid human cells results in an hTERT-dependent alteration of telomere length dynamics. Mol Cancer Res. 2008 Oct; 6(10):1582-93.
View in:
PubMed
CDK8 is a colorectal cancer oncogene that regulates beta-catenin activity. Nature. 2008 Sep 25; 455(7212):547-51.
View in:
PubMed
A prostatic intraepithelial neoplasia-dependent p27 Kip1 checkpoint induces senescence and inhibits cell proliferation and cancer progression. Cancer Cell. 2008 Aug 12; 14(2):146-55.
View in:
PubMed
Unexpected pieces to the senescence puzzle. Cell. 2008 Jun 13; 133(6):958-61.
View in:
PubMed
SV40 small T antigen and PP2A phosphatase in cell transformation. Cancer Metastasis Rev. 2008 Jun; 27(2):137-46.
View in:
PubMed
The current state of preclinical prostate cancer animal models. Prostate. 2008 May 01; 68(6):629-39.
View in:
PubMed
Regulation of in situ to invasive breast carcinoma transition. Cancer Cell. 2008 May; 13(5):394-406.
View in:
PubMed
The SIRT1 deacetylase suppresses intestinal tumorigenesis and colon cancer growth. PLoS One. 2008 Apr 16; 3(4):e2020.
View in:
PubMed
Feedback circuit among INK4 tumor suppressors constrains human glioblastoma development. Cancer Cell. 2008 Apr; 13(4):355-64.
View in:
PubMed
Multiple pathways regulated by the tumor suppressor PP2A in transformation. Trends Mol Med. 2008 Apr; 14(4):152-60.
View in:
PubMed
TERT promotes cellular and organismal survival independently of telomerase activity. Oncogene. 2008 Jun 12; 27(26):3754-60.
View in:
PubMed
Oncogenic transformation and experimental models of human cancer. Front Biosci. 2008 Jan 01; 13:71-84.
View in:
PubMed
Liprin alpha1 interacts with PP2A B56gamma. Cell Cycle. 2008 Feb 15; 7(4):525-32.
View in:
PubMed
Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev. 2007 Nov 01; 21(21):2683-710.
View in:
PubMed
Structural basis of PP2A inhibition by small t antigen. PLoS Biol. 2007 Aug; 5(8):e202.
View in:
PubMed
The role of PP2A A subunits in tumor suppression. Cell Adh Migr. 2007 Jul-Sep; 1(3):140-1.
View in:
PubMed
Integrative genomic approaches identify IKBKE as a breast cancer oncogene. Cell. 2007 Jun 15; 129(6):1065-79.
View in:
PubMed
The tumor suppressor PP2A Abeta regulates the RalA GTPase. Cell. 2007 Jun 01; 129(5):969-82.
View in:
PubMed
Simultaneous and exact interval estimates for the contrast of two groups based on an extremely high dimensional variable: application to mass spec data. Bioinformatics. 2007 Jun 15; 23(12):1451-8.
View in:
PubMed
Cancer genomics: integrating form and function. Carcinogenesis. 2007 Jul; 28(7):1387-92.
View in:
PubMed
Prostate cancer: Re-focusing on androgen receptor signaling. Int J Biochem Cell Biol. 2007; 39(9):1562-8.
View in:
PubMed
Role for the PP2A/B56delta phosphatase in regulating 14-3-3 release from Cdc25 to control mitosis. Cell. 2006 Nov 17; 127(4):759-73.
View in:
PubMed
Minimizing the risk of reporting false positives in large-scale RNAi screens. Nat Methods. 2006 Oct; 3(10):777-9.
View in:
PubMed
Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators. Cancer Cell. 2006 Oct; 10(4):321-30.
View in:
PubMed
Genome-scale loss-of-function screening with a lentiviral RNAi library. Nat Methods. 2006 Sep; 3(9):715-9.
View in:
PubMed
Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature. 2006 Aug 17; 442(7104):818-22.
View in:
PubMed
Comparative oncogenomics identifies NEDD9 as a melanoma metastasis gene. Cell. 2006 Jun 30; 125(7):1269-81.
View in:
PubMed
Androgen-dependent regulation of Her-2/neu in prostate cancer cells. J Clin Oncol. 2006 Jun 20; 24(18_suppl):10099.
View in:
PubMed
Androgen-dependent regulation of Her-2/neu in prostate cancer cells. Cancer Res. 2006 Jun 01; 66(11):5723-8.
View in:
PubMed
PP2A regulates BCL-2 phosphorylation and proteasome-mediated degradation at the endoplasmic reticulum. J Biol Chem. 2006 Aug 11; 281(32):23003-12.
View in:
PubMed
A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen. Cell. 2006 Mar 24; 124(6):1283-98.
View in:
PubMed
Roots and stems: stem cells in cancer. Nat Med. 2006 Mar; 12(3):296-300.
View in:
PubMed
Computational causal reasoning models of mechanisms of androgen stimulation in prostate cancer. Conf Proc IEEE Eng Med Biol Soc. 2006; 2006:38.
View in:
PubMed
Involvement of PP2A in viral and cellular transformation. Oncogene. 2005 Nov 21; 24(52):7746-55.
View in:
PubMed
Creating oral squamous cancer cells: a cellular model of oral-esophageal carcinogenesis. Proc Natl Acad Sci U S A. 2005 Oct 25; 102(43):15599-604.
View in:
PubMed
Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. PLoS Med. 2005 Nov; 2(11):e313.
View in:
PubMed
Cancer genetics: Finding the right mix. Eur J Hum Genet. 2005 Oct; 13(10):1099-100.
View in:
PubMed
Cancer-associated PP2A Aalpha subunits induce functional haploinsufficiency and tumorigenicity. Cancer Res. 2005 Sep 15; 65(18):8183-92.
View in:
PubMed
The Cdk1 complex plays a prime role in regulating N-myc phosphorylation and turnover in neural precursors. Dev Cell. 2005 Sep; 9(3):327-38.
View in:
PubMed
Transformation of human and murine fibroblasts without viral oncoproteins. Mol Cell Biol. 2005 Aug; 25(15):6464-74.
View in:
PubMed
Efficient inhibition of human telomerase reverse transcriptase expression by RNA interference sensitizes cancer cells to ionizing radiation and chemotherapy. Hum Gene Ther. 2005 Jul; 16(7):859-68.
View in:
PubMed
Identification of the androgen-induced transcriptional program of human prostate cancer revealed by causal analysis. J Clin Oncol. 2005 Jun; 23(16_suppl):4637.
View in:
PubMed
The telomerase reverse transcriptase regulates chromatin state and DNA damage responses. Proc Natl Acad Sci U S A. 2005 Jun 07; 102(23):8222-7.
View in:
PubMed
Analysis of telomeric single-strand overhang length in human endometrial cancers. FEBS Lett. 2005 May 23; 579(13):2959-64.
View in:
PubMed
Telomerase: regulation, function and transformation. Crit Rev Oncol Hematol. 2005 May; 54(2):85-93.
View in:
PubMed
Genetic alterations in prostate cancer. Clin Prostate Cancer. 2005 Mar; 3(4):220-9.
View in:
PubMed
Telomere and telomerase dynamics in human cells. Curr Mol Med. 2005 Mar; 5(2):227-31.
View in:
PubMed
Understanding transformation: progress and gaps. Curr Opin Genet Dev. 2005 Feb; 15(1):13-7.
View in:
PubMed
Androgen-induced differentiation and tumorigenicity of human prostate epithelial cells. Cancer Res. 2004 Dec 15; 64(24):8867-75.
View in:
PubMed
Signaling and transcriptional changes critical for transformation of human cells by simian virus 40 small tumor antigen or protein phosphatase 2A B56gamma knockdown. Cancer Res. 2004 Oct 01; 64(19):6978-88.
View in:
PubMed
Nucleolin interacts with telomerase. J Biol Chem. 2004 Dec 03; 279(49):51508-15.
View in:
PubMed
Cancer: surviving on the edge. Cancer Cell. 2004 Sep; 6(3):215-22.
View in:
PubMed
Expression of telomerase RNA template, but not telomerase reverse transcriptase, is limiting for telomere length maintenance in vivo. Mol Cell Biol. 2004 Aug; 24(16):7024-31.
View in:
PubMed
Indications for BRCA1 and BRCA2 mutation testing in hereditary breast and ovarian cancer families. J Clin Oncol. 2004 Jul 15; 22(14_suppl):9720.
View in:
PubMed
Functional genetics and experimental models of human cancer. Trends Mol Med. 2004 Jul; 10(7):344-50.
View in:
PubMed
Mitogen stimulation cooperates with telomere shortening to activate DNA damage responses and senescence signaling. Mol Cell Biol. 2004 Jun; 24(12):5459-74.
View in:
PubMed
Immortalized cells as experimental models to study cancer. Cytotechnology. 2004 Jun; 45(1-2):47-59.
View in:
PubMed
Experimental models of human cancer. Cell Cycle. 2004 May; 3(5):604-5.
View in:
PubMed
Viral vector-mediated transduction of a modified thrombospondin-2 cDNA inhibits tumor growth and angiogenesis. Gene Ther. 2004 May; 11(9):739-45.
View in:
PubMed
A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells. Nat Cell Biol. 2004 Apr; 6(4):308-18.
View in:
PubMed
A genetically defined model for human ovarian cancer. Cancer Res. 2004 Mar 01; 64(5):1655-63.
View in:
PubMed
Targeting cancer with telomerase: commentary re Q. Huang et al., a novel conditionally replicative adenovirus vector targeting telomerase-positive tumor cells. Clin. Cancer Res., 10: 1439-1445, 2004. Clin Cancer Res. 2004 Feb 15; 10(4):1203-5.
View in:
PubMed
In situ human telomerase reverse transcriptase expression pattern in normal and neoplastic ovarian tissues. Oncol Rep. 2004 Feb; 11(2):297-302.
View in:
PubMed
Identification of specific PP2A complexes involved in human cell transformation. Cancer Cell. 2004 Feb; 5(2):127-36.
View in:
PubMed
Vaccination of cancer patients against telomerase induces functional antitumor CD8+ T lymphocytes. Clin Cancer Res. 2004 Feb 01; 10(3):828-39.
View in:
PubMed
The origin of cancer. Cancer Treat Res. 2004; 122:1-22.
View in:
PubMed
New Functions for Telomerase. Cancer Res Treat. 2003 Dec; 35(6):467-71.
View in:
PubMed
Telomerase expression--only half the story. Cancer Biol Ther. 2003 Nov-Dec; 2(6):685-6.
View in:
PubMed
Protection against collagen-induced arthritis by intramuscular gene therapy with an expression plasmid for the interleukin-1 receptor antagonist. Gene Ther. 2003 Sep; 10(18):1543-50.
View in:
PubMed
Electro-gene therapy of collagen-induced arthritis by using an expression plasmid for the soluble p75 tumor necrosis factor receptor-Fc fusion protein. Gene Ther. 2003 Aug; 10(15):1216-24.
View in:
PubMed
Telomerase maintains telomere structure in normal human cells. Cell. 2003 Jul 25; 114(2):241-53.
View in:
PubMed
Evolving views of telomerase and cancer. Trends Cell Biol. 2003 Jun; 13(6):289-94.
View in:
PubMed
Telomerase and tumorigenesis. Cancer Lett. 2003 May 15; 194(2):163-72.
View in:
PubMed
Role of telomeres and telomerase in the pathogenesis of human cancer. J Clin Oncol. 2003 May 15; 21(10):2034-43.
View in:
PubMed
Human mammary epithelial cell transformation through the activation of phosphatidylinositol 3-kinase. Cancer Cell. 2003 May; 3(5):483-95.
View in:
PubMed
SV40 early region oncoproteins and human cell transformation. Histol Histopathol. 2003 04; 18(2):541-50.
View in:
PubMed
Lentivirus-delivered stable gene silencing by RNAi in primary cells. RNA. 2003 Apr; 9(4):493-501.
View in:
PubMed
Chemosensitivity linked to p73 function. Cancer Cell. 2003 Apr; 3(4):403-10.
View in:
PubMed
Abolition of cyclin-dependent kinase inhibitor p16Ink4a and p21Cip1/Waf1 functions permits Ras-induced anchorage-independent growth in telomerase-immortalized human fibroblasts. Mol Cell Biol. 2003 Apr; 23(8):2859-70.
View in:
PubMed
Erosion of the telomeric single-strand overhang at replicative senescence. Nat Genet. 2003 Apr; 33(4):492-6.
View in:
PubMed
Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells. Cancer Cell. 2003 Mar; 3(3):285-96.
View in:
PubMed
Rules for making human tumor cells. N Engl J Med. 2002 Nov 14; 347(20):1593-603.
View in:
PubMed
Empty pockets yield more telomere change. Cell Cycle. 2002 Nov-Dec; 1(6):406-7.
View in:
PubMed
Telomerase contributes to tumorigenesis by a telomere length-independent mechanism. Proc Natl Acad Sci U S A. 2002 Oct 01; 99(20):12606-11.
View in:
PubMed
Activation of Notch-1 signaling maintains the neoplastic phenotype in human Ras-transformed cells. Nat Med. 2002 Sep; 8(9):979-86.
View in:
PubMed
Immortalization and transformation of primary human airway epithelial cells by gene transfer. Oncogene. 2002 Jul 04; 21(29):4577-86.
View in:
PubMed
A two-stage, p16(INK4A)- and p53-dependent keratinocyte senescence mechanism that limits replicative potential independent of telomere status. Mol Cell Biol. 2002 Jul; 22(14):5157-72.
View in:
PubMed
Senescence, telomere shortening and telomere maintenance. Cancer Biol Ther. 2002 Jul-Aug; 1(4):398-400.
View in:
PubMed
Immortalization and transformation of human cells. Mol Cells. 2002 Jun 30; 13(3):351-61.
View in:
PubMed
Modelling the molecular circuitry of cancer. Nat Rev Cancer. 2002 May; 2(5):331-41.
View in:
PubMed
Enumeration of the simian virus 40 early region elements necessary for human cell transformation. Mol Cell Biol. 2002 Apr; 22(7):2111-23.
View in:
PubMed
Prospects for anti-neoplastic therapies based on telomere biology. Curr Cancer Drug Targets. 2002 Mar; 2(1):1-17.
View in:
PubMed
Derivation of human tumor cells in vitro without widespread genomic instability. Cancer Res. 2001 Dec 15; 61(24):8838-44.
View in:
PubMed
Equivalent induction of telomerase-specific cytotoxic T lymphocytes from tumor-bearing patients and healthy individuals. Cancer Res. 2001 Dec 01; 61(23):8366-70.
View in:
PubMed
Characterization of HLA-A3-restricted cytotoxic T lymphocytes reactive against the widely expressed tumor antigen telomerase. Clin Cancer Res. 2001 Nov; 7(11):3343-8.
View in:
PubMed
Telomerase and cancer: where and when? Clin Cancer Res. 2001 Oct; 7(10):2953-4.
View in:
PubMed
Cyclin D1 overexpression and p53 inactivation immortalize primary oral keratinocytes by a telomerase-independent mechanism. J Clin Invest. 2001 Sep; 108(5):725-32.
View in:
PubMed
Telomerase activation, cellular immortalization and cancer. Ann Med. 2001 Mar; 33(2):123-9.
View in:
PubMed
The Saccharomyces cerevisiae WRN homolog Sgs1p participates in telomere maintenance in cells lacking telomerase. EMBO J. 2001 Feb 15; 20(4):905-13.
View in:
PubMed
Human breast cancer cells generated by oncogenic transformation of primary mammary epithelial cells. Genes Dev. 2001 Jan 01; 15(1):50-65.
View in:
PubMed
Genes involved in senescence and immortalization. Curr Opin Cell Biol. 2000 Dec; 12(6):705-9.
View in:
PubMed
Complications during root canal irrigation--literature review and case reports. Int Endod J. 2000 May; 33(3):186-93.
View in:
PubMed
Human keratinocytes that express hTERT and also bypass a p16(INK4a)-enforced mechanism that limits life span become immortal yet retain normal growth and differentiation characteristics. Mol Cell Biol. 2000 Feb; 20(4):1436-47.
View in:
PubMed
Inhibition of telomerase limits the growth of human cancer cells. Nat Med. 1999 Oct; 5(10):1164-70.
View in:
PubMed
Creation of human tumour cells with defined genetic elements. Nature. 1999 Jul 29; 400(6743):464-8.
View in:
PubMed
The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity. 1999 Jun; 10(6):673-9.
View in:
PubMed
Dissociation among in vitro telomerase activity, telomere maintenance, and cellular immortalization. Proc Natl Acad Sci U S A. 1998 Dec 08; 95(25):14723-8.
View in:
PubMed
Diagnosis in Oncology. Leukemia cutis. J Clin Oncol. 1997 May; 15(5):2170-1.
View in:
PubMed
Intracellular mediators regulate CD2 lateral diffusion and cytoplasmic Ca2+ mobilization upon CD2-mediated T cell activation. Biophys J. 1995 Feb; 68(2):459-70.
View in:
PubMed
Separable portions of the CD2 cytoplasmic domain involved in signaling and ligand avidity regulation. J Exp Med. 1993 Nov 01; 178(5):1831-6.
View in:
PubMed
T cell adhesion, avidity regulation and signaling: a molecular analysis of CD2. Semin Immunol. 1993 Aug; 5(4):249-61.
View in:
PubMed
The complete sequences of plasmids pFNeo and pMH-Neo: convenient expression vectors for high-level expression of eukaryotic genes in hematopoietic cell lines. Gene. 1993 May 30; 127(2):267-8.
View in:
PubMed
Signal transduction pathways involved in T cell receptor-induced regulation of CD2 avidity for CD58. J Immunol. 1993 Apr 01; 150(7):2607-19.
View in:
PubMed
CD4, CD8 and CD2 in T cell adhesion and signaling. Curr Top Microbiol Immunol. 1993; 184:223-33.
View in:
PubMed
A distinct cytoplasmic domain of CD2 regulates ligand avidity and T-cell responsiveness to antigen. Proc Natl Acad Sci U S A. 1992 Aug 01; 89(15):7179-83.
View in:
PubMed
Overlapping but nonidentical binding sites on CD2 for CD58 and a second ligand CD59. Science. 1992 Jun 26; 256(5065):1805-7.
View in:
PubMed
CD43, a molecule defective in Wiskott-Aldrich syndrome, binds ICAM-1. Nature. 1991 Nov 21; 354(6350):233-5.
View in:
PubMed
Interaction of CD2 with its ligand lymphocyte function-associated antigen-3 induces adenosine 3',5'-cyclic monophosphate production in T lymphocytes. J Immunol. 1991 Jul 01; 147(1):14-21.
View in:
PubMed
Cloned cDNA sequence for the human mesothelial protein 'mesosecrin' discloses its identity as a plasminogen activator inhibitor (PAI-1) and a recent evolutionary change in transcript processing. J Cell Sci. 1989 Sep; 94 ( Pt 1):1-10.
View in:
PubMed
Mesosecrin: a secreted glycoprotein produced in abundance by human mesothelial, endothelial, and kidney epithelial cells in culture. J Cell Biol. 1987 Feb; 104(2):263-75.
View in:
PubMed
Cloning and sequence of DNA encoding structural proteins of the autonomous parvovirus feline panleukopenia virus. J Virol. 1985 Sep; 55(3):574-82.
View in:
PubMed
Clinical signs for the early recognition of cancer of the oral cavity. Int Dent J. 1977 Jun 02; 27(2):165-71.
View in:
PubMed
[Blood sugar and plasma insulin levels in children following the oral administration of glybenclamide (HB 419)]. Z Kinderheilkd. 1970; 108(1):32-40.
View in:
PubMed